[The current aspects of the use of ecstasy/MDMA in France]
Related Experiment Video
Updated: Mar 18, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Michel Spadari1, Anne Batisse2, Marylène Guerlais3
1Service de pharmacologie clinique et pharmacovigilance, centre d'addictovigilance PACA-Corse, CHU, 13005 Marseille, France.
Abstract:
Methylenedioxymethamphetamine (MDMA), the active compound of ecstasy, has been used for several years, especially by young adults to benefit of psychostimulant properties. By raising the level of neuromodulators in the synapsis, MDMA can cause psychiatric and physical injuries. After reduced supplies in 2009 (number of ecstasy seizures equal to 10 percent of those recorded in 2002), judicial authorities now observed an increased availability (a half more part of seizures in 2012 than 2010). From its "Spontaneous Notifications" data base and "deaths in connection with the abuse of medicine and substances (DRAMES)", "observation of illegal drugs and misuse of psychotropic medications" (OPPIDUM), and "observation of drug dependencies in ambulatory medicine" (OPEMA) national inquiries, the French Addictovigilance network (CEIP-A) highlighted the increasing consumption of MDMA. The way of use appeared quite unchanged: users were mainly young men between 25 and 30 years; they favored an occasional use but mainly combined other products such as alcohol, cannabis and other stimulants. Severity of the clinical cases, based on hospital care and forensic data, could be consistent with the higher amounts of MDMA measured in pills.
More Related Videos
Related Concept Videos
CNS Stimulants: Psychedelic Agents
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Therapeutic Drug Monitoring: Affecting Factors
Antidepressant Drugs: MAOIs and Other Agents
Therapeutic Drug Monitoring: Drug Analysis Methods

